Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
- M. Parmar, V. Torri, L. Stewart
- MedicineStatistics in Medicine
- 30 December 1998
A number of methods of extracting estimates of the log hazard ratio and its variance in a variety of situations are presented to improve the efficiency and reliability of meta-analyses of the published literature with survival-type endpoints.
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
- H. Ahmed, A. E. Bosaily, M. Emberton
- MedicineThe Lancet
- 25 February 2017
A phase 3 trial of bevacizumab in ovarian cancer.
In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer.
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
- D. Sebag‐Montefiore, R. Stephens, M. Parmar
- MedicineThe Lancet
- 7 March 2009
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- N. James, J. D. de Bono, M. Sydes
- MedicineNew England Journal of Medicine
- 3 June 2017
Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
- H. Kitchener, A. Swart, Q. Qian, C. Amos, M. Parmar
- MedicineThe Lancet
- 10 January 2009
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of…
- U. Menon, A. Gentry-Maharaj, I. Jacobs
- MedicineThe Lancet Oncology
- 1 April 2009
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- P. Royston, M. Parmar
- MathematicsBMC Medical Research Methodology
- 7 December 2013
It is concluded that the hazard ratio cannot be recommended as a general measure of the treatment effect in a randomized controlled trial, nor is it always appropriate when designing a trial.
...
...